Physician profile
Margaret M Runner
NPI 1902331986
$71,455.94
in general payments reported to CMS, 2019-2025
21 companies · $50K in 2025
The $50K reported for 2025 was more than what 97% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $553 · 2020: $318 · 2021: $511 · 2022: $1,488 · 2023: $2,509 · 2024: $16K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $18K · Honoraria: $9,518 · Food and Beverage: $7,520 · Travel and Lodging: $4,104 · Gift: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $29,434.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,000.00 |
| Honoraria | $9,518.25 |
| Food and Beverage | $7,519.61 |
| Travel and Lodging | $4,103.71 |
| Gift | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $20,595.14 | 2024-2025 | Izervay |
| Abbvie INC. | $15,956.89 | 2022-2025 | Ozurdex |
| Alcon Vision LLC | $9,009.91 | 2019-2025 | Unity, Constellation, Ngenuity |
| Alimera Sciences, INC. | $8,828.94 | 2022-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $8,323.99 | 2022-2025 | Susvimo, Vabysmo |
| Harrow Eye, LLC | $3,040.45 | 2024-2025 | Iheezo, Triesence |
| Apellis Pharmaceuticals, INC. | $2,749.46 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $1,133.97 | 2019-2025 | Eylea Hd, Eylea |
| Ani Pharmaceuticals, INC. | $471.77 | 2024-2025 | Purified Cortrophin Gel, Iluvien, Yutiq |
| Oculus Surgical INC. | $328.59 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $253.40 | 2022-2025 | Xipere |
| Iridex Corporation | $224.43 | 2024-2025 | |
| Sandoz INC. | $215.21 | 2024-2025 | Cimerli |
| Allergan, INC. | $99.99 | 2020 | |
| Ocular Therapeutix, INC. | $65.21 | 2024 | Dextenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $35.33 | 2025 | Eylea Hd |
| Mallinckrodt Hospital Products INC. | $29.65 | 2021 | |
| Biogen, INC. | $29.17 | 2022 | |
| Coherus Oncology, INC. | $26.47 | 2023 | |
| Eyepoint US, INC. | $22.95 | 2021 | |
| Dutch Ophthalmic, USA | $15.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Runner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.